ALPCO, a leading producer of research and clinical immunoassays, announced it will feature its therapeutic drug monitoring (TDM) ELISA portfolio at the AACC’s 70th Clinical Lab Expo July 31-August 2 in Chicago. ALPCO’s TDM ELISA Portfolio can aid researching the immunogenicity of biologics commonly used to treat inflammatory bowel disease (IBD). The offering features ten colorimetric ELISAs that measure free drug level, free anti-drug antibodies (ADAs), and total anti-drug antibodies for IBD biologics including infliximab and adalimumab.

“Although biologics have been used to treat IBD for many years, loss of response and primary non-response are still major issues which need to be better understood,” explains ALPCO’s president, Sean Conley. “Our TDM ELISAs allow researchers to confidently collect data in the context of these scenarios as they strive to develop methods for therapeutic drug monitoring to help personalize and improve IBD care.”

ALPCO’s comprehensive TDM ELISA portfolio offers a more reliable method to investigate optimal concentrations of a given biologic, and immune responses to an IBD biologic, as well as understand if ADAs are playing a role in the lack of response to a given IBD biologic.  

These assays are for research use only and not for use in diagnostic procedures in the United States. The Infliximab and Adalimumab Drug Level and Total ADA ELISAs, as well as the Infliximab Free ADA ELISA are Health Canada Licensed.

Visit ALPCO in booth #3467 at the AACC’s 70th Clinical Lab Expo to learn more about the therapeutic drug monitoring ELISA portfolio.


American Laboratory Products Company (ALPCO) was founded in 1991 as an importer and distributor of immunoassay-based products for the North American life science markets. The company has since grown into a premier channel representing over 60 collaborating partners from around the globe. Today, ALPCO offers a wide range of testing solutions, providing scientists and healthcare professionals with vital tools for advancing research and improving quality of care.